AndroGel Cost in New York 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is the Cash Price of AndroGel in New York in 2026?

The retail list price of AndroGel 1.62% sits at approximately $510 per month for a standard 30-day supply in New York. Without insurance or a discount card, that number hits your wallet directly. GoodRx-negotiated prices at chains like CVS, Walgreens, and Rite Aid in New York City and upstate markets have ranged from about $280 to $390 per month for the same supply in early 2026, depending on which specific dose strength (1% vs. 1.62%) and quantity you need.

Testosterone gel is a Schedule III controlled substance under federal law, which means the pharmacy must verify your prescription against a valid DEA-registered prescriber. New York State law mirrors this requirement. Price variation across boroughs is real: a 90-count pump bottle of AndroGel 1.62% at an independent pharmacy in Queens may carry a different negotiated rate than the same bottle at a national chain in Buffalo. Calling ahead with your GoodRx coupon code before you drive is worthwhile.

The FDA-approved labeling for AndroGel 1.62% specifies a starting dose of 40.5 mg testosterone (2 pump actuations) applied to the upper arm or shoulder once daily, with titration to 20.25 mg or up to 81 mg based on serum testosterone levels measured 14 days post-initiation. Full prescribing information is available via the FDA's accessdata portal. At 4 pumps per day (81 mg), a single bottle runs out faster, pushing your monthly cost toward the higher end of those quoted ranges.

A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found that out-of-pocket testosterone therapy costs drove a measurable proportion of patients to discontinue treatment within the first six months, underscoring why understanding every cost-reduction pathway before you fill your first prescription matters.

Does New York Medicaid Cover AndroGel?

New York Medicaid covers AndroGel for male hypogonadism, but a prior authorization (PA) is required. The PA process typically demands documented serum total testosterone below 300 ng/dL on two morning measurements taken on separate days, along with a diagnosis code consistent with hypogonadism (ICD-10 E29.1 for primary hypogonadism or E23.0 for secondary). Prescribers submit the PA through the eMedNY portal or through their electronic health record system.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We recommend testosterone therapy for men with classic androgen deficiency syndromes associated with unequivocally low serum testosterone levels, to induce and maintain secondary sex characteristics and correct symptoms." That guideline is the standard most New York Medicaid PA reviewers use when evaluating medical necessity. Read the full guideline at the Endocrine Society's site.

Managed Long Term Care (MLTC) plans and mainstream Medicaid managed care plans in New York (Fidelis, MetroPlus, Healthfirst, and others) each maintain their own preferred drug lists. Some list AndroGel as non-preferred and require a step-therapy fail with a generic testosterone gel first. Generic 1.62% testosterone gel entered the market following patent expiration and is typically covered at a lower tier, making it the path-of-least-resistance for Medicaid-enrolled patients in New York. FDA's Orange Book confirms therapeutic equivalents for testosterone gel.

If the PA is denied, your prescriber may appeal using the T-Trials data as supporting clinical evidence. The Testosterone Trials (T-Trials, N=788 men age 65 and older with total testosterone <275 ng/dL) demonstrated statistically significant improvements in sexual function, physical function, and bone density with testosterone gel compared to placebo over 12 months. The primary T-Trials results were published in NEJM, 2016. An endocrinologist or urologist's supporting letter citing that evidence can strengthen an appeal.

Which Commercial Insurance Plans Cover AndroGel in New York?

Most major commercial plans operating in New York, including Empire BlueCross BlueShield, United Healthcare, Aetna, Cigna, and Oscar Health, list testosterone gel on their formularies, generally at Tier 2 or Tier 3. Tier placement matters because it determines your copay or coinsurance.

A Tier 2 placement might mean a $45 to $75 monthly copay after your deductible. Tier 3 can push that to $90 to $150, and if you have a high-deductible health plan (HDHP), you pay the full negotiated rate until your deductible clears. The Kaiser Family Foundation's 2024 Employer Health Benefits Survey found the average individual HDHP deductible at $2,793, meaning many New Yorkers pay full price for AndroGel for the first two to four months of the calendar year.

Step therapy is common. Plans may require you to try and document an inadequate response or intolerance to a generic testosterone gel before covering brand-name AndroGel. New York State's step therapy law (NY Insurance Law Section 3217-d) gives patients the right to request a step-therapy exemption if their physician certifies that the required prior treatment is contraindicated, likely to cause harm, or was previously tried and failed. The New York State Department of Financial Services explains step-therapy rights here.

Prior authorization is required by virtually every commercial plan in New York. Approval turnaround averages three to five business days. Your prescriber's office should submit clinical notes showing two low testosterone values, symptom documentation, and the specific diagnosis code.

How Does the AbbVie myAbbVie Assist Savings Card Work in New York?

AbbVie offers two separate programs depending on your insurance status. For commercially insured patients, the AbbVie myAbbVie Assist copay card may reduce the monthly copay to as low as $0, with a maximum annual benefit that AbbVie adjusts periodically. As of early 2026, the program cap has been set at approximately $4,800 per calendar year for eligible patients.

The card does not apply to federal or state government insurance programs, meaning New York Medicaid, Medicare Part D, Medicaid Advantage, or any plan fully funded by New York State is excluded by federal anti-kickback statute rules. Patients on those programs cannot use the manufacturer copay card. The Office of Inspector General's guidance on manufacturer copay assistance makes that restriction clear for programs subject to federal healthcare law.

For uninsured or underinsured patients who meet income criteria, AbbVie's separate myAbbVie Assist patient assistance program may provide AndroGel at no cost. Eligibility is income-based and requires annual renewal. Applications are submitted through AbbVie's patient services line or the program's online portal.

To activate the copay card in New York, you present it at the pharmacy counter alongside your prescription. The card processes like a secondary insurance and typically reduces what you owe at point of sale. Some pharmacies require the pharmacist to manually key in the BIN/PCN/group numbers printed on the card if the system does not automatically recognize it.

What Discount Programs Are Available for AndroGel in New York?

Several third-party discount programs reduce AndroGel's cash price at New York pharmacies. GoodRx is the most widely used and consistently shows prices between $280 and $390 at large chains in the five boroughs and suburban markets. Blink Health and RxSaver negotiate similar rates. Mark Cuban's Cost Plus Drugs does not currently carry brand-name AndroGel, though it does list generic testosterone gel at substantially lower prices.

A 2022 analysis in Health Affairs found that GoodRx prices were lower than commercial insurance copays for approximately 23% of the most commonly prescribed drugs, testosterone gel included in the hormonal drug category that showed large discrepancies. If your Tier 3 copay exceeds the GoodRx price, paying cash with the coupon and skipping your insurance claim may save money, though doing so means the spending does not count toward your deductible.

NeedyMeds.org lists additional state-specific programs. New York residents who are uninsured and do not meet AbbVie's income threshold may qualify for sliding-scale services at Federally Qualified Health Centers (FQHCs) across the state, where testosterone prescribing happens alongside subsidized pharmacy dispensing. The HRSA FQHC finder locates nearby centers.

Below is a decision framework for choosing your cost pathway before your first fill:

Step 1. Confirm your diagnosis with two morning total testosterone values <300 ng/dL. Without documentation, no insurance or PA process moves forward.

Step 2. Check your insurance formulary tier for testosterone gel (generic first, then brand AndroGel). If generic is covered at Tier 1 or Tier 2, start there. Clinical outcomes between generic 1.62% testosterone gel and AndroGel are equivalent based on FDA bioequivalence standards.

Step 3. If commercially insured and AndroGel is preferred by your prescriber, apply the AbbVie copay card. If your copay after the card still exceeds the GoodRx price, use GoodRx instead.

Step 4. If on New York Medicaid, submit the PA with T-Trials citation support and request generic testosterone gel as the preferred agent to reduce PA friction.

Step 5. If uninsured and income-qualifying, apply to myAbbVie Assist patient assistance or explore 503A compounded testosterone gel at $90 to $120 per month.

Is Compounded Testosterone Gel Legal in New York?

Compounded testosterone gel is legal in New York when prepared by a pharmacy operating under a 503A license issued by the New York State Board of Pharmacy. These pharmacies compound patient-specific prescriptions, meaning the prescriber must write for a specific patient rather than for office stock or resale. The FDA's guidance on 503A compounding distinguishes patient-specific 503A compounding from the FDA-registered 503B outsourcing facility model.

New York State Board of Pharmacy oversight is strict. Compounding pharmacies in New York must comply with USP Chapter 795 standards for non-sterile preparations (testosterone gel is non-sterile), maintain accurate records, and pass periodic state inspections. USP 795 standards are referenced in FDA guidance documents.

The clinical trade-off matters. Compounded testosterone gels are not FDA-approved, so lot-to-lot potency variability is a genuine concern. A 2017 study in JAMA Internal Medicine found meaningful potency variability in sampled compounded testosterone products, with some preparations outside the 90 to 110% label potency range that FDA requires for approved drugs. For patients where precise dose titration is important (for example, men trying to maintain testosterone in the 500 to 700 ng/dL range for fertility preservation) that variability may affect outcomes.

Cost, though, is real. At $90 to $120 per month for a compounded 1% or 2% testosterone gel versus $510 list price for AndroGel, the savings over 12 months reach $4,680 to $5,040. For uninsured patients, that gap is clinically relevant because it determines whether they stay on therapy at all. Adherence data from a 2021 paper in Andrology showed that cost was the most commonly cited barrier to testosterone therapy continuation among self-pay patients.

Testosterone is a Schedule III controlled substance. Compounding pharmacies in New York must hold a DEA registration to handle it, and prescribers must use tamper-resistant prescription pads for written prescriptions or comply with e-prescribing security standards for electronic ones. DEA's controlled substance regulations are at deadiversion.usdoj.gov.

Can You Get AndroGel via Telehealth in New York?

Telehealth prescribing of AndroGel is legal in New York in 2026. The Ryan Haight Online Pharmacy Consumer Protection Act generally requires an in-person medical evaluation before a controlled substance can be prescribed via telemedicine, but the DEA's telemedicine rules have evolved since the COVID-19 public health emergency. As of 2025, the DEA's proposed special registration pathway for telemedicine prescribing of controlled substances remains under rulemaking, and in the interim, prescribers with a DEA registration may prescribe Schedule III substances via telemedicine to patients with whom they have established a valid provider-patient relationship that meets state law requirements. The DEA's telemedicine framework is described at deadiversion.usdoj.gov.

New York State's telehealth statute (NY Public Health Law Section 2999-cc) requires that telehealth services meet the same standard of care as in-person visits. A prescriber ordering AndroGel via telehealth must review lab results (serum testosterone, LH, FSH, hematocrit, and PSA at baseline per Endocrine Society recommendations), document symptoms consistent with hypogonadism, and establish medical necessity before the first prescription is transmitted electronically to a New York-licensed pharmacy. The Endocrine Society's 2018 guideline specifies baseline laboratory evaluation requirements that telehealth providers must replicate.

Telehealth TRT platforms operating in New York, including services that prescribe brand or compounded testosterone gel, must employ prescribers licensed in New York State. Patients should verify that the platform's physician or NP holds a New York license before submitting labs or payment. The New York State Education Department's Office of the Professions maintains a license verification database at op.nysed.gov.

A 2023 JAMA Network Open study found that telemedicine encounters for testosterone therapy increased 43% between 2019 and 2022 nationally, with New York among the top-five states by volume. Access improvements were concentrated among men aged 30 to 50 in suburban zip codes with limited endocrinology coverage. That finding suggests telehealth is filling a real gap, not just a convenience feature.

What Lab Work Is Required Before Filling AndroGel in New York?

Before any pharmacy in New York will dispense AndroGel, a valid prescription from a DEA-registered, New York-licensed prescriber is required. That prescription must follow from a clinical evaluation that includes specific laboratory testing. The Endocrine Society's guideline recommends: total serum testosterone (measured before 10 AM on two separate occasions), LH and FSH to differentiate primary from secondary hypogonadism, PSA for men over 40, hematocrit, and a full symptom assessment. See the Endocrine Society's full guideline.

LabCorp and Quest Diagnostics both operate patient service centers throughout New York and accept orders from telehealth platforms and in-person providers. Total testosterone with free testosterone reflex can be ordered for under $60 through direct-pay lab programs like Ulta Lab Tests or Walk-In Lab. Quest Diagnostics test menu lists exact pricing for self-pay patients.

Monitoring labs are equally important. The Endocrine Society recommends checking serum testosterone 14 days after starting or adjusting dose, then at 3 months, then annually once the patient is stable. Hematocrit should be checked at 3 and 6 months because testosterone gel raises red blood cell mass. A 2010 study in the Journal of Clinical Endocrinology and Metabolism found that transdermal testosterone raised hematocrit by a mean of 3.1 percentage points over 12 months, less than intramuscular testosterone cypionate but still clinically significant in men with baseline hematocrit above 48%. New York pharmacies will refill AndroGel prescriptions on the prescriber's schedule, but most responsible TRT providers build monitoring lab requirements into their refill authorization process.

How Does AndroGel Compare to Other Testosterone Formulations in New York?

AndroGel is one of several testosterone delivery options available in New York. Each formulation has a different cost structure. Testosterone cypionate 200 mg/mL injectable (1 mL every two weeks) costs approximately $35 to $70 per month cash pay at New York pharmacies, making it the least expensive FDA-approved option. Testosterone undecanoate (Aveed, intramuscular injection every 10 weeks) carries a much higher acquisition cost and requires in-office administration because of REMS program requirements. The Aveed REMS program details are at FDA.gov.

Testopel pellets (subcutaneous implants lasting 3 to 6 months) are available through urologists and some primary care practices in New York, with procedure costs of $500 to $900 per implant session. Natesto (intranasal testosterone) costs roughly $400 to $500 per month. A 2019 comparative review in Therapeutic Advances in Urology outlined the pharmacokinetic differences across formulations, noting that gels produce more stable serum testosterone levels compared to weekly injections but require daily application and carry a transfer-to-female-partner risk that injections do not.

For New York patients focused purely on cost, compounded testosterone cypionate injectable followed by compounded testosterone gel is the most economical path. For those who want an FDA-approved product with consistent potency and a manufacturer savings program, AndroGel 1.62% with the AbbVie copay card is competitive when commercially insured. The American Urological Association's 2022 testosterone deficiency guideline states formulation choice should account for patient preference, lifestyle, monitoring burden, and cost, with no formulation designated superior for all patients.

What Are the Clinical Risks That Affect Prescribing Eligibility in New York?

Understanding cost pathways is only half the picture. Some patients cannot use testosterone gel at all, and those contraindications apply regardless of insurance status or pharmacy in New York. Absolute contraindications include known or suspected prostate cancer, male breast cancer, and polycythemia. Relative contraindications include severe obstructive sleep apnea not on treatment, hematocrit above 54%, and uncontrolled heart failure. The FDA's 2015 safety communication on testosterone and cardiovascular risk required label updates across all testosterone products.

The TRAVERSE trial (N=5,246 men aged 45 to 80 with hypogonadism and high cardiovascular risk) reported that testosterone replacement therapy did not significantly increase the rate of major adverse cardiovascular events (MACE) compared to placebo over a mean follow-up of 33 months. TRAVERSE results were published in NEJM in 2023. That finding has reduced some prescribers' hesitation about testosterone therapy in cardiovascular-risk patients, though caution remains appropriate for men with recent MI or stroke within the prior six months.

Skin transfer to female partners or children is the most cited practical risk with testosterone gel. AndroGel's label specifies applying only to covered areas, washing hands after application, and covering the application site with clothing before contact. The FDA's MedWatch database includes reported pediatric virilization cases from gel transfer.

Infertility is a functional contraindication for men trying to conceive. Exogenous testosterone suppresses LH and FSH, shutting down spermatogenesis. A 2014 paper in Fertility and Sterility documented azoospermia in men on testosterone gel at rates approaching 40% after six months of use. Men in New York pursuing fertility should ask their prescriber about alternatives such as clomiphene citrate, human chorionic gonadotropin (hCG), or selective estrogen receptor modulators before starting testosterone gel.

Monitoring and Refill Logistics at New York Pharmacies

AndroGel is a Schedule III controlled substance. In New York, Schedule III prescriptions may be written for up to a 30-day supply and may carry up to five refills within six months of the original prescription date. After six months, a new prescription is required. Electronic prescribing for controlled substances (EPCS) is mandatory in New York State per Section 281 of the New York Public Health Law, meaning paper prescriptions for AndroGel are no longer accepted at most pharmacies unless the prescriber has received a specific exemption from the Department of Health.

New York's EPCS law details are available at the Department of Health's website. Most major pharmacy chains in New York have fully integrated EPCS systems. Mail-order pharmacies operating under New York pharmacy licenses can also dispense Schedule III prescriptions under EPCS, enabling a 30-day supply to ship directly to the patient's address, which is particularly convenient for telehealth patients who lack a nearby participating pharmacy.

The Prescription Monitoring Program Registry (PMP Registry), operated by the New York State Department of Health, records every controlled substance dispensed in New York. Prescribers and pharmacists are required to check the PMP before prescribing or dispensing AndroGel to identify potential misuse patterns. The PMP Registry is described at health.ny.gov.